Heparins Designed to Specifically Inhibit Platelet Interactions With von Willebrand Factor

Author:

Sobel Michael1,Bird Karyn E.1,Tyler-Cross Ruth1,Marques Dalila1,Toma Naoto1,Edward Conrad H.1,Harris Robert B.1

Affiliation:

1. From the Division of Vascular Surgery (M.S., K.E.B., D.M., N.T.) and Department of Biochemistry and Biophysics (R.T.-C., R.B.H.), Medical College of Virginia, Virginia Commonwealth University (Richmond); H.H. McGuire Veterans Affairs Medical Center (M.S., K.E.B., D.M., N.T., R.T.-C., R.B.H.), Richmond, Va; Department of Biochemistry (H.E.C.), University of Illinois (Urbana); and Glycomed Inc (H.E.C.), Alameda, Calif.

Abstract

Background Platelet interactions with the injured vessel wall may contribute significantly to the early and late failures of many cardiovascular interventions; the adhesive protein von Willebrand factor (vWF) is thought to play an important role. Previously, we demonstrated that heparin interfered with platelet/vWF hemostatic mechanisms by binding to vWF within the protein’s domain responsible for binding the platelet vWF receptor, glycoprotein Ib. The purpose of the present study was to develop and refine heparins with greater potency to inhibit platelet/vWF interactions. Methods and Results Immobilized synthetic peptides based on a known heparin-binding domain of vWF were used to yield novel fractions of standard heparin that demonstrated a sevenfold increase in their ability to inhibit vWF-dependent platelet agglutination and vWF/platelet binding. The high vWF affinity heparin showed enhanced anti–factor Xa activity but comparable activated partial thromboplastin time activity. Chemical modification of a standard heparin by periodate oxidation and borohydride reduction enhanced its ability to inhibit platelet/vWF interactions by threefold, while eliminating more than 90% of its activated partial thromboplastin time and anti–factor Xa activity. Affinity chromatography of the chemically modified heparin yielded a heparin with an eightfold higher inhibitory potency than the original heparin. Conclusions Subspecies of heparin can be developed with significantly enhanced potency to inhibit vWF/platelet interactions. The vWF-inhibiting property of heparin can be dissociated from its antithrombin-binding activity. Based on a growing understanding of heparin/vWF interactions, combinations of affinity separations and chemical modifications could be designed to yield heparins uniquely suitable for prevention of arterial thrombosis.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Physiology (medical),Cardiology and Cardiovascular Medicine

Reference45 articles.

1. von Willebrand factor and von Willebrand disease [published erratum appears in Blood 1988 Mar;71(3):830]

2. Hawiger J. Adhesive interactions of blood cells and the vascular wall. In: Colman RW Hirsh J Marder VJ Salzman EW eds. Hemostasis and Thrombosis . Philadelphia Pa: JB Lippincott Co; 1994:762-796.

3. Von Willebrand Factor and Platelet Function

Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3